Marinus Pharmaceuticals (NASDAQ:MRNS) Downgraded to Neutral at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a neutral rating in a research report report published on Wednesday morning, Marketbeat reports.

A number of other brokerages also recently weighed in on MRNS. Robert W. Baird reaffirmed a neutral rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. HC Wainwright reissued a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Finally, Truist Financial reaffirmed a buy rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $12.75.

Marinus Pharmaceuticals Stock Up 4.5 %

Marinus Pharmaceuticals stock traded up $0.05 on Wednesday, hitting $1.15. 85,168 shares of the stock traded hands, compared to its average volume of 1,235,760. The business’s fifty day simple moving average is $1.34 and its 200 day simple moving average is $4.42. The firm has a market cap of $63.17 million, a P/E ratio of -0.42 and a beta of 1.13. The company has a current ratio of 3.07, a quick ratio of 2.93 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 1 year low of $1.05 and a 1 year high of $11.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC raised its stake in Marinus Pharmaceuticals by 31.4% during the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after buying an additional 990,607 shares during the last quarter. Franklin Resources Inc. increased its position in Marinus Pharmaceuticals by 1.3% during the fourth quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company’s stock valued at $41,675,000 after acquiring an additional 49,589 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Marinus Pharmaceuticals by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares during the period. Acadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals in the second quarter worth about $813,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $727,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.